Corporate Overview
With facilities in Montreal, Quebec and Menlo Park, California, Caprion has been providing proteomics biomarker and target identification services since 2002, and has performed over fifty large-scale biomarker discovery and validation projects for over twenty major pharmaceutical industry clients from North America, Europe, and Asia in virtually every major disease indication.
Caprion’s rapidly growing service business offers:
Biomarker Services
- Biomarker discovery - CellCarta®
- Multiplexed Multiple Reaction Monitoring assays for rapid biomarker validation (MRM)
In-vitro Diagnostics
- Infectious disease
- Diabetes
- Oncology
- CNS
Drug Targets
- Oncology cell-surface targets for antibodytherapy and Dx imaging
- Infectious disease vaccine and antibiotic targets
Experience and Industrialized Process Make the Difference
Through many years of practical experience, Caprion’s highly trained, multi-disciplinary team has developed a highly integrated, industrialized approach to proteomics that reduces variability and provides meaningful results. Standardized procedures from sample collection to mass spec and data analysis provide our clients reproducible data that are routinely validated across large sets of clinical samples with rapid development and deployment MRM (Multiple Reaction Monitoring) assays.
Results from the many studies conducted over the past ten years has provided validation of Caprion's robust and industrialized proteomics approach to biomarker discovery and validation.
In addition to our broad range of pharmaceutical and biotech sponsored programs, Caprion also has been awarded two consecutive 5-year US$13 million contracts for Biodefense proteomics research in the area of infectious diseases with the NIH-NIAID.
In 2008, Caprion also entered into a worldwide strategic marketing and distribution alliance for biomarker services with Covance, Inc. (NYSE:CVD), which also involved the purchase by Covance of a minority equity stake in the company.